Active Treatment vs Expectant Management of Patent Ductus Arteriosus in Preterm Infants
Aktive Behandlung vs abwartendes Vorgehen bei offenem Ductus arteriosus bei Frühgeborenen
JAMA Pediatrics · 01.08.2025 · 179 (8) · 877
DOI: 10.1001/jamapediatrics.2025.1025 ↗Auf einen Blick
Eine Metaanalyse von 10 RCTs mit 2.035 Frühgeborenen fand unter aktiver Behandlung häufiger Tod oder mittel- bis schwere BPD als unter abwartendem Vorgehen.
Fragestellung
Verbessert eine aktive Behandlung des hämodynamisch signifikanten PDA bei Frühgeborenen die klinischen Outcomes im Vergleich zum abwartenden Vorgehen?
Methode
Metaanalyse von 10 RCTs; Datenbanken: PubMed (MEDLINE), Embase und Cochrane Library; Suche nach RCTs von 1. Januar 2010 bis 31. Juli 2024; Cochrane Risk of Bias Tool; Random-effects-Modell.
Ergebnisse
10 RCTs mit 2.035 Frühgeborenen. Primärer zusammengesetzter Endpunkt: 56,2 % vs. 50,8 %; RR 1,10 (95 %-KI 1,01–1,19). Tod mit 36 Wochen: 14,3 % vs. 11,2 %; RR 1,27 (95 %-KI 1,01–1,61).
Schlussfolgerung der Autor:innen
Die Metaanalyse ergab, dass eine aktive Behandlung des hämodynamisch signifikanten PDA in den ersten 2 Lebenswochen mit einer höheren Rate an Tod oder mittel- bis schwerer BPD und mit höherer Mortalität verbunden war. Weitere Forschung ist nötig.
Kernaussagen
- Primärer Endpunkt unter aktiver Behandlung häufiger: RR 1,10 (95 %-KI 1,01–1,19)
- Tod mit 36 Wochen unter aktiver Behandlung häufiger: RR 1,27 (95 %-KI 1,01–1,61)
- Keine signifikanten Unterschiede bei moderater bis schwerer BPD und PVL
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Pediatrics, erschienen am 01.08.2025. Verfasst von Santosi Buvaneswarran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Khoo Teck Puat National University Children's Medical Institute, National University Hospital, National University Health …. Hauptthemen laut MEDLINE: Ductus Arteriosus, Patent, Infant, Premature, Diseases, Watchful Waiting. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Neonatologie
Abstract (Originalsprache)
Importance Recent evidence suggests that expectant management of hemodynamically significant patent ductus arteriosus (PDA) may confer better outcomes.
Objective
To assess clinical outcomes of active treatment vs expectant management of hemodynamically significant PDA in preterm infants. Data Sources The PubMed (MEDLINE), Embase, and Cochrane Library databases were searched for randomized clinical trials (RCTs) published between January 1, 2010, and July 31, 2024. Study Selection RCTs were included if they enrolled preterm infants born before 33 weeks of gestation and had 2 groups comparing active treatment with expectant management. Data Extraction and Synthesis The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed. Data were extracted by 2 independent reviewers. The Cochrane Risk of Bias tool was used to assess study quality. A random-effects model was used to estimate the pooled effects. Main Outcomes and Measures The primary outcomes were a composite of death at 36 weeks’ postmenstrual age or at discharge (whichever occurred later) or moderate to severe bronchopulmonary dysplasia (BPD), death at 36 weeks, and moderate to severe BPD. Secondary outcomes included intraventricular hemorrhage, periventricular leukomalacia (PVL), retinopathy of prematurity, and necrotizing enterocolitis.
Results
This meta-analysis included 10 RCTs involving 2035 infants. There were 1018 infants in the active treatment group (510 female [50.1%]) and 1017 infants (551 male [54.2%]) in the expectant management group. The mean (SD) gestational age was 26.2 (1.7) weeks vs 26.3 (1.7) weeks, and the mean (SD) birth weight was 874.7 (222.1) g vs 897.7 (216.5) g, respectively. The incidence of the composite outcome (death at 36 weeks or at discharge or moderate to severe BPD) was higher in the active treatment group vs the expectant management group (516 of 918 [56.2%] vs 465 of 915 [50.8%]; relative risk [RR], 1.10 [95% CI, 1.01-1.19]; P = .02). Deaths at 36 weeks were higher in the active treatment group (139 of 974 [14.3%] vs 109 of 969 [11.2%]; RR, 1.27 [95% CI, 1.01-1.61]; P = .04). There were nonsignificant increases in moderate to severe BPD (372 of 785 [47.4%] vs 349 of 806 [43.3%]; RR, 1.08 [95% CI, 0.95-1.23]; P = .25) and PVL (52 of 913 [5.7%] vs 32 of 908 [3.5%]; RR, 1.50 [95% CI, 0.98-2.30]; P = .06) in the active treatment group vs the expectant management group. Conclusions and Relevance This meta-analysis found that active treatment of hemodynamically significant PDA during the first 2 weeks of life was associated with a significantly higher incidence of death or moderate to severe BPD and with increased mortality compared with an expectant management approach. Further research is needed for revision of protocols for PDA management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neonatology, Khoo Teck Puat National University Children's Medical Institute, National University Hospital, National University Health System, Singapore.
- Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Department of Paediatrics, Khoo Teck Puat National University Children's Medical Institute, National University Hospital, National University Health System, Singapore.
Zitieren
APA
Buvaneswarran, S., Wong, Y. L., Liang, S., Quek, S. C., & Lee, J. (2025). Active Treatment vs Expectant Management of Patent Ductus Arteriosus in Preterm Infants. JAMA Pediatrics, 179(8), 877. https://doi.org/10.1001/jamapediatrics.2025.1025
Vancouver
Buvaneswarran S, Wong YL, Liang S, Quek SC, Lee J. Active Treatment vs Expectant Management of Patent Ductus Arteriosus in Preterm Infants. JAMA Pediatrics. 2025;179(8):877. doi:10.1001/jamapediatrics.2025.1025
BibTeX
@article{Buvaneswarran2025,
author = {Buvaneswarran, Santosi and Wong, Yi Ling and Liang, Shen and Quek, Swee Chye and Lee, Jiun},
title = {Active Treatment vs Expectant Management of Patent Ductus Arteriosus in Preterm Infants},
journal = {JAMA Pediatrics},
year = {2025},
volume = {179},
number = {8},
pages = {877},
doi = {10.1001/jamapediatrics.2025.1025}
}
EUVIMED